GITR modulates innate and adaptive mucosal immunity during the development of experimental colitis in mice

Santucci, L.; Agostini, M.; Bruscoli, S.; Mencarelli, A.; Ronchetti, S.; Ayroldi, E.; Morelli, A.; Baldoni, M.; Riccardi, C.
January 2007
Gut;Jan2007, Vol. 56 Issue 1, p52
Academic Journal
Background: Uncontrolled T cell activation and abnormal function of the innate immune system against normal enteric bacterial flora play a critical part in the pathogenesis of inflammatory bowel disease (IBD). Therefore, pharmacological strategies directed to restore the normal responsiveness of the immune system could be efficacious in the treatment of these pathological conditions. Glucocorticoid-induced tumour necrosis factor receptor (GITR)-related gene is a member of the tumour necrosis factor receptor superfamily that is constitutively expressed at high levels on regulatory T cells and at low levels on unstimulated I cells, B cells and macrophages. GIIR triggering leads to activation of I effectors and reversal of suppressive function of regulatory T cells. Aim: To investigate the role of GITR in the development of experimental colitis in mice. Results: Using GITR-/- mice, GITR deletion protected against 2,4,6-trinitrobenzene sulphonic acid (TNBS)- induced colitis by reducing innate immune responses and effector T cell activity. Effector T cells isolated from GITR-/- mice were less effective than T cells isolated from GITR+/+ mice to transfer colitis in immunodeficient mice. Blocking the GITR/ligand for GITR (GiTRL) signal by giving soluble GITR prevented TNBS-induced colitis in normal GITR+/+ and also in lymphocyte-deficient SCID mice. Conclusions: Collectively, these data suggest that GITR plays a critical part in regulating both acquired and innate mucosal immune responses during the development of experimental colitis in mice. Therefore, targeting the GITR/GITRL system signalling may represent a potential pharmacological tool for the treatment of IBD.


Related Articles

  • Tumor Necrosis Factor Blockade for Treatment of Inflammatory Bowel Disease: Efficacy and Safety. Ngo, Benjamin; Farrell, Christopher P.; Barr, Maura; Wolov, Kevin; Bailey, Robert; Mullin, James M.; Thornton, James J. // Current Molecular Pharmacology;Nov2010, Vol. 3 Issue 3, p145 

    Inflammatory bowel disease (IBD), including Crohn's Disease (CD) and Ulcerative Colitis (UC), is characterized by inflammation of the gastrointestinal tract. In UC, inflammation is confined to the mucosa, initially involving the rectum, and may extend proximally to involve the entire colon. In...

  • Stem Cells in Inflammatory Bowel Disease: New Potential Therapeutic Target. In Hwan Song; Byung Ik Jang // Intestinal Research;2013, Vol. 11 Issue 2, p79 

    Understanding of the pathophysiology of inflammatory bowel disease (IBD) is constantly evolving and, recently, a number of biologic agents that selectively target specific molecules or pathways to correct the imbalance of the gut immune system have been developed. Among them, an antibody to...

  • Control of matrix metalloproteinase production in human intestinal fibroblasts by interleukin 21. Monteleone, G.; Caruso, R.; Fina, D.; Peluso, I.; Gioia, V.; Stolfi, C.; Fantini, M. C.; Caprioli, F.; Tersigni, R.; Alessandroni, L.; MacDonald, T. T.; Pallone, F. // Gut;Dec2006, Vol. 55 Issue 12, p1774 

    Background: T cell-mediated immunity plays a central part in the pathogenesis of tissue damage in inflammatory bowel disease (IBD). The mechanism by which T cells mediate tissue damage during IBD remains unclear, but evidence indicates that T cell-derived cytokines stimulate fibroblasts to...

  • Hepatosplenic T cell lymphoma in inflammatory bowel disease. Shale, Matthew; Kanfer, Ed; Panaccione, Remo; Ghosh, Subrata // Gut;Dec2008, Vol. 57 Issue 12, p1639 

    The article discusses the enhancement of lymphoma in inflammatory bowel disease (IBD). It mentions that thiopurine therapy has possibility to cause risk of lynmphoma. The experts state the appearance of hepatosplenic T cell lymphoma (HSTCL) in the patients of IBD who are displayed with...

  • Dysregulated LIGHT expression on T cells mediates intestinal inflammation and contributes to IgA nephropathy. Jing Wang; Anders, Robert A.; Qiang Wu; Dacheng Peng; Cho, Judy H.; Sun, Yonglian; Karaliukas, Reda; Hyung-Sik Kang; Turner, Jerrold R.; Yang-Xin Fu // Journal of Clinical Investigation;Mar2004, Vol. 113 Issue 6, p826 

    Whether and how T cells contribute to the pathogenesis of immunoglobulin A nephropathy (IgAN) has not been well defined. Here, we explore a murine model that spontaneously develops T cell-mediated intestinal inflammation accompanied by pathological features similar to those of human IgAN....

  • Epithelial myosin light chain kinase expression and activity are upregulated in inflammatory bowel disease. Blair, Stephanie A.; Kane, Sunanda V.; Clayburgh, Daniel R.; Turner, Jerrold R. // Laboratory Investigation (00236837);Feb2006, Vol. 86 Issue 2, p191 

    The intestinal epithelial barrier is frequently disrupted in inflammatory bowel disease (IBD) and this has been proposed to play a role in disease pathogenesis and reactivation. In vitro studies show that cytokine-induced epithelial barrier dysfunction can be mediated by increased myosin light...

  • Current Opinion in the Pharmaceutical Management of Irritable and Inflammatory Bowel Diseases: Role of ATP. Salari, Pooneh; Abdollahi, Mohammad // Recent Patents on Endocrine, Metabolic & Immune Drug Discovery;Jan2009, Vol. 3 Issue 1, p69 

    Inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) are two chronic intestinal diseases having a mutual pathophysiological pathways with different manifestations. Generally, inflammatory mediators and cytokines orchestrate the scenario that amongst them, tumor necrosis...

  • Prolonged Duration of Response to Infliximab in Early But Not Late Pediatric Crohn's Disease. Kugathasan, Subra; Werlin, Steven L.; Martinez, Alfonzo; Rivera, Maria T.; Heikenen, Janice B.; Binion, David G. // American Journal of Gastroenterology;Nov2000, Vol. 95 Issue 11, p3189 

    OBJECTIVES: Tumor necrosis factor-α plays a central role in chronic intestinal inflammation of Crohn's disease. Targeting this cytokine with the chimeric monoclonal antibody infliximab has emerged as an effective form of therapy in adult Crohn's disease patients. We sought to determine...

  • Treatment of Crohn Disease with Anti--Tumor Necrosis Factor Agent.  // Annals of Internal Medicine;6/19/2007, Vol. 146 Issue 12, pI20 

    The article examines the effectiveness regarding the use of anti-tumor necrosis factor agent in treating patients with Crohn's disease. A chronic inflammatory bowel disease, the symptoms of Crohn' disease include diarrhea, fever and abdominal pain. Key information about the methods and results...


Read the Article


Sign out of this library

Other Topics